• Moderna published phase I study results for adjuvant intismeran autogene with FOLFIRINOX in 20 patients with resected pancreatic ductal adenocarcinoma.
• Neoantigen-specific T-cell responses were detected in all 19 evaluable patients, including during concurrent chemotherapy.
• At median follow-up of approximately 17 months, 11 patients remained recurrence-free.
• One patient experienced grade 3 intismeran-related fatigue; no adverse events led to intismeran discontinuation.
• No deaths were reported; analyses were descriptive, with no formal hypothesis testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.